Compression behaviour of salicylic acid powder in veterinary tablet and bolus dosage forms is governed by particle size distribution, crystal habit, residual moisture and the free acid’s tendency to sublime at temperatures above 76°C at 1 mmHg. The API is typically milled and screened through a 40-mesh sieve before dry blending with microcrystalline cellulose, spray-dried lactose monohydrate and crospovidone at target tablet weights between 500 mg and 1.5 g for swine and bovine indications. Powder flow is characterised using USP <1174>; unmilled salicylic acid with a needle-like crystal habit generally shows a Hausner ratio above 1.35, which is reduced by wet granulation or by adding 0.5–1.0% w/w colloidal silicon dioxide. Rotary tablet presses with 10–16 station tooling and compaction pressures of 120–180 MPa are used for direct compression; punch sticking and capping are controlled by maintaining loss on drying below 0.5% and by using chromium-plated or tungsten carbide punches. Disintegration is tested according to USP <701>, and dissolution profiling for immediate-release tablets uses USP <711> Apparatus 2 at 50 rpm in phosphate buffer pH 7.4 or hydrochloric acid pH 1.2. Because salicylic acid is a chelating agent, titanium dioxide and iron oxide pigments can accelerate colour shifts in coated tablets; film coating with hydroxypropyl methylcellulose is therefore applied in a perforated pan coater with inlet air temperature not exceeding 60°C.

Why Does Injectable Formulation Design Require pH Adjustment and Cosolvent Screening?

Salicylic acid powder dissolves slowly in water, with a solubility of approximately 1 g in 460 mL at 20°C, but it is freely soluble in ethanol and propylene glycol. Injectable solutions for cattle, swine or companion animals therefore require either a mixed-solvent system or in-situ salt formation to achieve a therapeutically relevant concentration. For aqueous injections, the free acid is neutralized with sodium hydroxide solution to a target pH of 6.5–7.5, at which the ionized salicylate form predominates and solubility increases sharply. The neutralization step is performed with continuous cooling because the acid-base reaction is exothermic; stainless steel 316L vessels with chilled jackets are used to keep the bulk solution below 30°C during pH adjustment. Propylene glycol or glycerin is added at 30–50% v/v as a cosolvent and stabilizer before terminal sterilization at 121°C for 15 min. Finished parenteral solutions are filtered through 0.22 µm polyethersulfone membrane filters and filled into amber borosilicate glass vials under nitrogen overlay. Particulate matter is controlled according to USP <788> limits for large-volume injections, and bacterial endotoxins are tested per USP <85>; a limit of 0.5 EU/mg is calculated when the maximum dose is 10 mg/kg body weight and the threshold pyrogenic dose is 5 EU/kg. The solution must be protected from light and from trace iron because salicylic acid forms violet or red chelates with ferric ions, producing visible discoloration and accelerating oxidative degradation. Stability studies place related substances by HPLC according to Ph. Eur. method 2.2.29; total impurities above 0.2% indicate breakdown and require a reduction in headspace oxygen or the addition of sodium metabisulfite at 0.1% w/v.

Premix Granule Segregation Thresholds and Moisture Uptake in Medicated Drinking Water Lines

In medicated drinking water premix manufacture, salicylic acid powder is converted into effervescent or non-effervescent granules to improve dispersibility, reduce dust and stabilize the free acid against atmospheric moisture. A dry blend of salicylic acid, anhydrous citric acid and sodium bicarbonate is granulated in a high-shear mixer such as a Diosna or Lödige unit with impeller speed 300–500 rpm and chopper speed 1500–2000 rpm; because the acid and bicarbonate react in the presence of water, the granulation solvent is either anhydrous ethanol or a non-aqueous binder solution containing povidone at 3–5% w/w. The citric acid-to-sodium bicarbonate ratio is balanced at 1:3 molar equivalents to ensure complete gas generation without residual alkalinity. The granulated mass is wet-milled through a 4–6 mm screen, dried in a fluid-bed dryer at 45–55°C until loss on drying is below 0.5%, and then dry-milled to a D90 below 250 µm with a D10 above 50 µm. This size band limits segregation during pneumatic conveying and maintains rapid hydration when the premix is added to drinking water for swine or poultry. The reconstituted solution is mixed for 10–15 min in a stainless steel dosing tank and adjusted to pH 7.0–7.8; salicylate solutions used in open drinking water lines should be consumed within 24 h to prevent microbial proliferation and oxidative loss. Carryover in medicated feed lines is measured by cleaning validation protocols based on a target carryover limit of 1% of the minimum therapeutic dose; analytical detection is performed by HPLC with UV detection at 303 nm according to Ph. Eur. 2.2.29. Packaging in aluminum foil laminate sachets with desiccant sachets is required where storage relative humidity exceeds 60%.

When Salicylic Acid Is Filled into Hard Gelatin Capsules in Veterinary Compounding Pharmacies

The low bulk density and poor flow of unmilled salicylic acid powder create fill-weight variability in hard gelatin capsule operations; capsule formulations therefore require dry blending with spray-dried lactose monohydrate, microcrystalline cellulose and sodium starch glycolate before filling on a semi-automatic or automatic capsule machine. Target fill weights between 250 mg and 500 mg for size 0 or size 1 capsules are used for companion animal or equine dose units. Powder bed uniformity is assessed using USP <905> uniformity of dosage units, while capsule disintegration is tested according to USP <2040> with a limit of 30 min in water at 37°C. Because salicylic acid is a weak organic acid with a pKa of 2.97, it can acidify the immediate microenvironment inside gelatin capsules; at relative humidity above 60%, the resulting moisture uptake accelerates gelatin shell hydrolysis and crosslinking. Capsules are therefore stored in HDPE bottles with silica gel desiccant sachets and sealed with induction foil liners. In compounding practice, the API is dispensed in a low-humidity pharmacy cleanroom with relative humidity below 40%, and powders are geometrically diluted to avoid local concentration gradients. The free acid is incompatible with alkaline fillers such as magnesium carbonate or calcium carbonate because visible effervescence and salt formation alter disintegration and dissolution; formulation trials should replace these with mannitol or dibasic calcium phosphate dihydrate when a basic filler is required.

Medicated solutions and shampoos for companion animal dermatology use salicylic acid powder as a keratolytic, antiseborrheic and bacteriostatic agent at finished concentrations of 2.0–5.0% w/w. The bulk solution is prepared by dissolving the acid in a co-solvent system of ethanol, propylene glycol and deionized water while maintaining a pH of 3.0–3.8; at this pH the unionized free acid predominates and can penetrate hyperkeratotic scale. pH adjustment is performed after complete dissolution; addition of triethanolamine to neutralise carbomer must be carried out only after the salicylic acid solution has been thickened, otherwise the amine reacts with the free acid and reduces both keratolytic activity and viscosity. The viscosity of the finished shampoo is measured using USP <911> with a Brookfield rotational viscometer at 20 rpm and 25°C, targeting 1500–3000 mPa·s for a pumpable veterinary shampoo. The solution is mixed in a 316L stainless steel vessel with a propeller stirrer at 100–150 rpm until clear; undissolved crystals are removed by filtration through a 100 µm nylon bag filter. Stability assessment under 40°C / 75% RH for 6 months or 25°C / 60% RH for 24 months follows Ph. Eur. 5.1.3 or USP <1150> for pharmaceutical stability. Because the free acid precipitates when the formulation pH rises above 5.5, amine-functional surfactants and strongly alkaline thickening systems are avoided; nonionic surfactants such as polysorbate 80 at 1–2% w/w are used to maintain clarity.

Dusting Powders and Hoof Dressings Require Controlled Particle Adhesion Under High-Humidity Barn Conditions

For topical dusting powders intended for cattle and equine hoof care, salicylic acid powder is formulated with absorbent carriers such as kaolin, talc or zinc oxide to promote adhesion to moist skin and interdigital surfaces. The particle size band that balances respirable-fraction reduction and surface coverage places the D90 between 150 µm and 300 µm, while the D10 is maintained above 45 µm to reduce airborne fines. The powder is screened through a 60-mesh sieve and blended in a double-cone or ribbon blender fitted with intensifier bars; blending time is limited to 15–20 min at 10–15 rpm to prevent segregation caused by density differences between salicylic acid and mineral carriers. Packing is carried out in low-permeability polyethylene-lined kraft bags or plastic pails with desiccant sachets where barn relative humidity exceeds 70%; salicylic acid powder can cake on storage if moisture uptake exceeds 0.5%. The final topical powder is not terminally sterilized; microbial limits are controlled according to USP <61> and <62>, with total aerobic microbial count below 10² CFU/g and absence of Staphylococcus aureus and Pseudomonas aeruginosa per 1 g. The product is applied in a well-ventilated area, and occupational exposure to respirable salicylic acid dust is controlled by local exhaust ventilation because the free acid is irritating to respiratory mucosa; because regulatory OEL values vary by jurisdiction, no harmonized OEL is published for this compound and powder containment follows a risk-based occupational health assessment with routine air monitoring.